Form 4 for NGNE Neurogene Inc.
Accepted 2025-03-28 00:00:00 ET · period of report 2025-03-26 · accession 0001404644-25-000023 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-28 | 2025-03-26 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +20.3K | 92.6K | +28% | $0 |
| D | 2025-03-28 | 2025-03-26 | NGNE | Cvijic Christine Mikail | Pres, CFO | A - Grant | $0.00 | +122.0K | 122.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-26 | A | A | 20,300 | $0.00 | 92,643 | D | — | — | (F1) Consist of 20,300 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date. (F2) Includes 24,000 shares held jointly by the reporting person and her spouse, David Cvijic. |
| 2 | Derivative | Employee Stock Option (Right to buy) | 2025-03-26 | A | A | 122,000 | $0.00 | 122,000 | D | $16.14 · — to 2035-03-26 | 122,000 Common Stock | (F3) This option represents the right to purchase 122,000 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the date of grant with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date. |